ORIGINAL ARTICLE – Financial Post, March 30, 2022
TORONTO — VoxNeuro Inc. (“VoxNeuro” or the “Company”), a Software as a Medical Device (SaMD) brain health company that analyzes brain-based biomarkers to assess cognitive function, announced a number of significant developments including (i) receipt of US patent 11278230 entitled “Systems and methods for cognitive health assessment” which provides protection for VoxNeuro’s competitive advantage (specific EEG-based neuropsychological assessments that generate event-related potentials associated with key cognitive functions, and the output of a cognitive health report), (ii) the establishment of a US-based expert clinical study program to assist in expanding VoxNeuro’s product offerings across a range of neurological pathologies, and (iii) the retainer of a seasoned executive, Jason Flowerday, as Chief Executive Officer.
Mr. Flowerday joins VoxNeuro as it prepares to solidify its product development plans and pipeline. Following the launch of its first product in the Spring of 2021, a SaMD general cognitive assessment that healthcare providers leverage in clinical decision-making, VoxNeuro is in the process of formalizing partnerships with channel partners to assist with its roll-out across the United States. In parallel, the Company is working to finalize its initial clinical programs with leading American institutions and medical specialists to develop a series of valuable diagnostic products in the areas of Depression, Concussion, Alzheimer’s, Schizophrenia and Bi-polar disorder. The Company expects that these clinical programs will commence in the second half of 2022.
To continue reading CLICK HERE.
